Use of anticoagulant but not antiplatelet therapy prior to transplantation was associated with an increased risk of bleeding complications, without adversely affecting short-term allograft function. These results suggest that anticoagulant and antiplatelet therapies may be continued until the time of organ offer in select patients, and apixaban may be a suitable alternative to warfarin for patients on the transplant waiting list.
Lavery et al. (Sun,) studied this question.